ACS chemical neuroscience molecule spotlight on Potiga (Ezogabine).
On June 10th, 2011, the U.S. Food and Drug Administration approved Potiga (ezogabine) as an add-on medication for the treatment of seizures in adults, and it is being developed by Valeant Pharmaceuticals.
Vanderbilt Center for Neuroscience Drug Discovery, Department of Pharmacology and Chemistry, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee 37232-6600, USA.
Corey R
CR
Hopkins
D000927:Anticonvulsants / Q000494:pharmacology* / Q000627:therapeutic use; D002219:Carbamates / Q000494:pharmacology* / Q000627:therapeutic use; D004827:Epilepsy / Q000188:drug therapy; D006801:Humans; D051656:KCNQ Potassium Channels / Q000819:agonists; D010655:Phenylenediamines / Q000494:pharmacology* / Q000627:therapeutic use; D015221:Potassium Channels / Q000819:agonists; D016032:Randomized Controlled Trials as Topic; D012640:Seizures / Q000517:prevention & control; D014481:United States; D014486:United States Food and Drug Administration
D000927:Anticonvulsants; D002219:Carbamates; D051656:KCNQ Potassium Channels; D010655:Phenylenediamines; D015221:Potassium Channels; C101866:ezogabine